Physician profile
Daniel Brelian
NPI 1700032497
$128,512.34
in general payments reported to CMS, 2019-2025
25 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $9,745 · 2021: $35K · 2022: $22K · 2023: $17K · 2024: $10K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $7,640 · Honoraria: $1,250 · Travel and Lodging: $1,113 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,802.50 |
| Food and Beverage | $7,639.60 |
| Honoraria | $1,250.00 |
| Travel and Lodging | $1,112.62 |
| Education | $118.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $100,796.86 | 2019-2025 | Linzess, Mavyret, Skyrizi |
| Madrigal Pharmaceuticals | $16,559.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,970.90 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Ironwood Pharmaceuticals, INC | $2,136.85 | 2019-2024 | Linzess |
| Alcresta Therapeutics, INC. | $1,370.90 | 2023 | Relizorb |
| Celgene Corporation | $909.49 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $739.18 | 2019-2025 | |
| Janssen Biotech, INC. | $710.34 | 2019-2025 | Stelara, Tremfya |
| Redhill Biopharma INC. | $574.28 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Pfizer INC. | $367.31 | 2024-2025 | |
| Qol Medical, LLC | $326.70 | 2019-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $138.02 | 2019-2025 | Sutab, Suflave |
| Ardelyx, INC. | $134.54 | 2024-2025 | Ibsrela |
| Endogastric Solutions, INC | $125.99 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $113.39 | 2021-2024 | Dificid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $107.69 | 2020-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $83.64 | 2025 | Zenpep, Vowst |
| Boston Scientific Corporation | $79.87 | 2023-2024 | Bodyguardian |
| Phathom Pharmaceuticals, INC. | $70.17 | 2025 | Voquezna |
| Genzyme Corporation | $66.74 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.83 | 2021-2025 | Entyvio |
| Amgen INC. | $29.25 | 2021 | |
| Shionogi INC | $23.95 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $22.59 | 2023 | Evusheld |
| Alfasigma USA, INC. | $19.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brelian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.